Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Chemotherapy of leishmaniasis: present challenges

Full text
Uliana, Silvia R. B. [1] ; Trinconi, Cristiana T. [1] ; Coelho, Adriano C. [2, 1]
Total Authors: 3
[1] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Ave Prof Lineu Prestes 1374, BR-05508000 Sao Paulo - Brazil
[2] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, Campinas, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: Parasitology; v. 145, n. 4, SI, p. 464-480, APR 2018.
Web of Science Citations: 30

Cutaneous and visceral leishmaniasis are amongst the most devastating infectious diseases of our time, affecting millions of people worldwide. The treatment of these serious diseases rely on a few chemotherapeutic agents, most of which are of parenteral use and induce severe side-effects. Furthermore, rates of treatment failure are high and have been linked to drug resistance in some areas. Here, we reviewed data on current chemotherapy practice in leishmaniasis. Drug resistance and mechanisms of resistance are described as well as the prospects for applying drug combinations for leishmaniasis chemotherapy. It is clear that efforts for discovering new drugs applicable to leishmaniasis chemotherapy are essential. The main aspects on the various steps of drug discovery in the field are discussed. (AU)

FAPESP's process: 15/09080-2 - Evaluation of candidate drugs for the treatment of Leishmaniasis in Brazil
Grantee:Silvia Reni Bortolin Uliana
Support type: Regular Research Grants
FAPESP's process: 12/14629-5 - Mechanisms of action and resistance to miltefosine in Leishmania spp.
Grantee:Adriano Cappellazzo Coelho
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 15/23832-7 - New approaches to circumvent shortcomings of leishmaniasis treatment: design of an in vitro visceral leishmaniasis model based on the organs-on-a-chip technology and testing of strategies to revert antimony resistance
Grantee:Cristiana de Melo Trinconi Tronco
Support type: Scholarships in Brazil - Post-Doctorate